Technical Analysis for RPRX - Royalty Pharma plc
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
Multiple of Ten Bullish | Other | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Pocket Pivot | Bullish Swing Setup | -0.13% | |
Multiple of Ten Bullish | Other | -0.13% | |
NR7 | Range Contraction | 0.67% | |
Doji - Bullish? | Reversal | 0.67% | |
Multiple of Ten Bearish | Other | 0.67% | |
Fell Below 20 DMA | Bearish | 0.57% | |
Multiple of Ten Bearish | Other | 0.57% |
Alert | Time |
---|---|
Possible NR7 | about 17 hours ago |
Possible Inside Day | about 17 hours ago |
60 Minute Opening Range Breakdown | about 21 hours ago |
10 DMA Support | about 21 hours ago |
Fell Below 10 DMA | about 21 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/15/2024
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Pharmaceutical Products Drug Development HIV Biopharmaceutical Products
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Pharmaceutical Products Drug Development HIV Biopharmaceutical Products
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 37.1552 |
52 Week Low | 25.5437 |
Average Volume | 2,748,206 |
200-Day Moving Average | 28.78 |
50-Day Moving Average | 29.32 |
20-Day Moving Average | 30.34 |
10-Day Moving Average | 29.99 |
Average True Range | 0.65 |
RSI (14) | 52.15 |
ADX | 17.02 |
+DI | 21.64 |
-DI | 17.43 |
Chandelier Exit (Long, 3 ATRs) | 29.70 |
Chandelier Exit (Short, 3 ATRs) | 31.17 |
Upper Bollinger Bands | 31.44 |
Lower Bollinger Band | 29.25 |
Percent B (%b) | 0.37 |
BandWidth | 7.23 |
MACD Line | 0.17 |
MACD Signal Line | 0.27 |
MACD Histogram | -0.0974 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 30.56 | ||||
Resistance 3 (R3) | 30.55 | 30.38 | 30.47 | ||
Resistance 2 (R2) | 30.38 | 30.25 | 30.38 | 30.45 | |
Resistance 1 (R1) | 30.21 | 30.17 | 30.12 | 30.22 | 30.42 |
Pivot Point | 30.04 | 30.04 | 29.99 | 30.04 | 30.04 |
Support 1 (S1) | 29.87 | 29.91 | 29.79 | 29.88 | 29.68 |
Support 2 (S2) | 29.70 | 29.83 | 29.70 | 29.65 | |
Support 3 (S3) | 29.53 | 29.70 | 29.63 | ||
Support 4 (S4) | 29.54 |